Accurate measurements of galaxy masses and sizes are key to tracing galaxy evolution over time. Cosmological zoom-in simulations provide an ideal test bed for assessing the recovery of galaxy ...properties from observations. Here, we utilize galaxies with at z ∼ 1.7-2 from the MassiveFIRE cosmological simulation suite, part of the Feedback in Realistic Environments (FIRE) project. Using mock multi-band images, we compare intrinsic galaxy masses and sizes to observational estimates. We find that observations accurately recover stellar masses, with a slight average underestimate of and scatter. Recovered half-light radii agree well with intrinsic half-mass radii when averaged over all viewing angles, with a systematic offset of (with the half-light radii being larger) and a scatter of . When using color gradients to account for mass-to-light variations, recovered half-mass radii also exceed the intrinsic half-mass radii by . However, if not properly accounted for, aperture effects can bias size estimates by . No differences are found between the mass and size offsets for star-forming and quiescent galaxies. Variations in viewing angle are responsible for ∼25% of the scatter in the recovered masses and sizes. Our results thus suggest that the intrinsic scatter in the mass-size relation may have previously been overestimated by ∼25%. Moreover, orientation-driven scatter causes the number density of very massive galaxies to be overestimated by at .
The 3D-HST and CANDELS programs have provided WFC3 and ACS spectroscopy and photometry over approximate900 arcmin super(2) in five fields: AEGIS, COSMOS, GOODS-North, GOODS-South, and the UKIDSS UDS ...field. All these fields have a wealth of publicly available imaging data sets in addition to the Hubble Space Telescope (HST) data, which makes it possible to construct the spectral energy distributions (SEDs) of objects over a wide wavelength range. In this paper we describe a photometric analysis of the CANDELS and 3D-HST HST imaging and the ancillary imaging data at wavelengths 0.3-8Mum. Objects were selected in the WFC3 near-IR bands, and their SEDs were determined by carefully taking the effects of the point-spread function in each observation into account. A total of 147 distinct imaging data sets were used in the analysis. The photometry is made available in the form of six catalogs: one for each field, as well as a master catalog containing all objects in the entire survey. We also provide derived data products: photometric redshifts, determined with the EAZY code, and stellar population parameters determined with the FAST code. We make all the imaging data that were used in the analysis available, including our reductions of the WFC3 imaging in all five fields. 3D-HST is a spectroscopic survey with the WFC3 and ACS grisms, and the photometric catalogs presented here constitute a necessary first step in the analysis of these grism data. All the data presented in this paper are available through the 3D-HST Web site (http://3dhst.research.yale.edu).
Emerging evidence suggests that shortened, simplified treatment regimens for rifampicin-resistant tuberculosis (RR-TB) can achieve comparable end-of-treatment (EOT) outcomes to longer regimens. We ...compared a 6-month regimen containing bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) to a standard of care strategy using a 9- or 18-month regimen depending on whether fluoroquinolone resistance (FQ-R) was detected on drug susceptibility testing (DST).
The primary objective was to determine whether 6 months of BPaLM is a cost-effective treatment strategy for RR-TB. We used genomic and demographic data to parameterize a mathematical model estimating long-term health outcomes measured in quality-adjusted life years (QALYs) and lifetime costs in 2022 USD ($) for each treatment strategy for patients 15 years and older diagnosed with pulmonary RR-TB in Moldova, a country with a high burden of TB drug resistance. For each individual, we simulated the natural history of TB and associated treatment outcomes, as well as the process of acquiring resistance to each of 12 anti-TB drugs. Compared to the standard of care, 6 months of BPaLM was cost-effective. This strategy was estimated to reduce lifetime costs by $3,366 (95% UI: 1,465, 5,742 p < 0.001) per individual, with a nonsignificant change in QALYs (-0.06; 95% UI: -0.49, 0.03 p = 0.790). For those stopping moxifloxacin under the BPaLM regimen, continuing with BPaL plus clofazimine (BPaLC) provided more QALYs at lower cost than continuing with BPaL alone. Strategies based on 6 months of BPaLM had at least a 93% chance of being cost-effective, so long as BPaLC was continued in the event of stopping moxifloxacin. BPaLM for 6 months also reduced the average time spent with TB resistant to amikacin, bedaquiline, clofazimine, cycloserine, moxifloxacin, and pyrazinamide, while it increased the average time spent with TB resistant to delamanid and pretomanid. Sensitivity analyses showed 6 months of BPaLM to be cost-effective across a broad range of values for the relative effectiveness of BPaLM, and the proportion of the cohort with FQ-R. Compared to the standard of care, 6 months of BPaLM would be expected to save Moldova's national TB program budget $7.1 million (95% UI: 1.3 million, 15.4 million p = 0.002) over the 5-year period from implementation. Our analysis did not account for all possible interactions between specific drugs with regard to treatment outcomes, resistance acquisition, or the consequences of specific types of severe adverse events, nor did we model how the intervention may affect TB transmission dynamics.
Compared to standard of care, longer regimens, the implementation of the 6-month BPaLM regimen could improve the cost-effectiveness of care for individuals diagnosed with RR-TB, particularly in settings with a high burden of drug-resistant TB. Further research may be warranted to explore the impact and cost-effectiveness of shorter RR-TB regimens across settings with varied drug-resistant TB burdens and national income levels.
ABSTRACT We present reduced data and data products from the 3D-HST survey, a 248-orbit HST Treasury program. The survey obtained WFC3 G141 grism spectroscopy in four of the five CANDELS fields: ...AEGIS, COSMOS, GOODS-S, and UDS, along with WFC3 H140 imaging, parallel ACS G800L spectroscopy, and parallel I814 imaging. In a previous paper, we presented photometric catalogs in these four fields and in GOODS-N, the fifth CANDELS field. Here we describe and present the WFC3 G141 spectroscopic data, again augmented with data from GO-1600 in GOODS-N (PI: B. Weiner). We developed software to automatically and optimally extract interlaced two-dimensional (2D) and one-dimensional (1D) spectra for all objects in the Skelton et al. (2014) photometric catalogs. The 2D spectra and the multi-band photometry were fit simultaneously to determine redshifts and emission line strengths, taking the morphology of the galaxies explicitly into account. The resulting catalog has redshifts and line strengths (where available) for 22,548 unique objects down to (79,609 unique objects down to ). Of these, 5459 galaxies are at and 9621 are at , where H falls in the G141 wavelength coverage. The typical redshift error for galaxies is , i.e., one native WFC3 pixel. The limit for emission line fluxes of point sources is erg s−1 cm−2. All 2D and 1D spectra, as well as redshifts, line fluxes, and other derived parameters, are publicly available.18
ABSTRACT
The combination of the MOSDEF and KBSS-MOSFIRE surveys represents the largest joint investment of Keck/MOSFIRE time to date, with ∼3000 galaxies at 1.4 ≲ z ≲ 3.8, roughly half of which are ...at z ∼ 2. MOSDEF is photometric- and spectroscopic-redshift selected with a rest-optical magnitude limit, while KBSS-MOSFIRE is primarily selected based on rest-UV colours and a rest-UV magnitude limit. Analysing both surveys in a uniform manner with consistent spectral-energy-distribution (SED) models, we find that the MOSDEF z ∼ 2 targeted sample has higher median M* and redder rest U−V colour than the KBSS-MOSFIRE z ∼ 2 targeted sample, and smaller median SED-based SFR and sSFR (SFR(SED) and sSFR(SED)). Specifically, MOSDEF targeted a larger population of red galaxies with U−V and V−J ≥1.25, while KBSS-MOSFIRE contains more young galaxies with intense star formation. Despite these differences in the z ∼ 2 targeted samples, the subsets of the surveys with multiple emission lines detected and analysed in previous work are much more similar. All median host-galaxy properties with the exception of stellar population age – i.e. M*, SFR(SED), sSFR(SED), AV, and UVJ colours – agree within the uncertainties. Additionally, when uniform emission-line fitting and stellar Balmer absorption correction techniques are applied, there is no significant offset between both samples in the O iiiλ5008/H β versus N iiλ6585/H α diagnostic diagram, in contrast to previously reported discrepancies. We can now combine the MOSDEF and KBSS-MOSFIRE surveys to form the largest z ∼ 2 sample with moderate-resolution rest-optical spectra and construct the fundamental scaling relations of star-forming galaxies during this important epoch.
Botulinum toxin type-A for the treatment of inverse psoriasis Zanchi, M; Favot, F; Bizzarini, M ...
JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology,
April 2008, Volume:
22, Issue:
4
Journal Article
Peer reviewed
Open access
Objective To evaluate the efficacy of botulinum toxin type‐A (BoNTA) for the treatment of inverse psoriasis.
Background The use of BoNTA in inverse psoriasis would be a novel approach compared with ...conventional treatments and may act at the neuroglandular junction level to reduce local sweating with its consequent skin maceration and secondary infection and at the extra‐junction level to inhibit the liberation of neuropeptides and other pro‐algogenic substances responsible for inflammation, hyperkeratosis and pain transmission.
Patients Fifteen patients with a confirmed diagnosis of inverse psoriasis were enrolled into the study. The psoriasis was located in several areas: armpits (7 patients), submammary sulcus (6 patients), intergluteal folds (7 patients), inguinal folds (5 patients) and umbilicus (1 patient).
Methods BoNTA treatment comprised individual injections 2.8 cm apart of 2.4 U BoNTA, with a total dosage between 50 and 100 U per patient depending on the extent and severity of the psoriasis. Patient assessments were done pre‐treatment and at 2, 4 and 12 weeks post‐treatment. The erythematous area was defined using objective photographic evidence, and subjective patient assessment of pain and itch was assessed using a 10‐point visual analogue scale scale.
Results Subjective symptomatology improved in all patients and erythema extension, intensity and infiltration improved in 13 of 15 patients (87%). Treatment was well tolerated with no reported adverse events.
Conclusions BoNTA therapy resulted in improvements in subjective patient symptomatology and objective reductions in erythema and maceration in the treated areas according to photographic evidence. Further large‐scale methodologically rigorous studies are required to investigate the safety and efficacy of BoNTA in this indication.
ObjectivesCOVID-19 has altered health sector capacity in low-income and middle-income countries (LMICs). Cost data to inform evidence-based priority setting are urgently needed. Consequently, in this ...paper, we calculate the full economic health sector costs of COVID-19 clinical management in 79 LMICs under different epidemiological scenarios.MethodsWe used country-specific epidemiological projections from a dynamic transmission model to determine number of cases, hospitalisations and deaths over 1 year under four mitigation scenarios. We defined the health sector response for three base LMICs through guidelines and expert opinion. We calculated costs through local resource use and price data and extrapolated costs across 79 LMICs. Lastly, we compared cost estimates against gross domestic product (GDP) and total annual health expenditure in 76 LMICs.ResultsCOVID-19 clinical management costs vary greatly by country, ranging between <0.1%–12% of GDP and 0.4%–223% of total annual health expenditure (excluding out-of-pocket payments). Without mitigation policies, COVID-19 clinical management costs per capita range from US$43.39 to US$75.57; in 22 of 76 LMICs, these costs would surpass total annual health expenditure. In a scenario of stringent social distancing, costs per capita fall to US$1.10–US$1.32.ConclusionsWe present the first dataset of COVID-19 clinical management costs across LMICs. These costs can be used to inform decision-making on priority setting. Our results show that COVID-19 clinical management costs in LMICs are substantial, even in scenarios of moderate social distancing. Low-income countries are particularly vulnerable and some will struggle to cope with almost any epidemiological scenario. The choices facing LMICs are likely to remain stark and emergency financial support will be needed.
Exacerbations of COPD are defined clinically by worsening of chronic respiratory symptoms. Chronic respiratory symptoms are common in the general population. There are no data on the frequency of ...exacerbation-like events in individuals without spirometric evidence of COPD.
To determine the occurrence of 'exacerbation-like' events in individuals without airflow limitation, their associated risk factors, healthcare utilisation and social impacts.
We analysed the cross-sectional data from 5176 people aged 40 years and older who participated in a multisite, population-based study on lung health. The study cohort was stratified into spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and non-COPD (post bronchodilator FEV1/FVC ≥ 0.7 and without self-reported doctor diagnosis of airway diseases) subgroups and then into those with and without respiratory 'exacerbation-like' events in the past year.
Individuals without COPD had half the frequency of 'exacerbation-like' events compared with those with COPD. In the non-COPD group, the independent associations with 'exacerbations' included female gender, presence of wheezing, the use of respiratory medications and self-perceived poor health. In the non-COPD group, those with exacerbations were more likely than those without exacerbations to have poorer health-related quality of life (12-item Short-Form Health Survey), miss social activities (58.5% vs 18.8%), miss work for income (41.5% vs 17.3%) and miss housework (55.6% vs 16.5%), p<0.01 to <0.0001.
Events similar to exacerbations of COPD can occur in individuals without COPD or asthma and are associated with significant health and socioeconomic outcomes. They increase the respiratory burden in the community and may contribute to the false-positive diagnosis of asthma or COPD.
Objectives To determine the costs of Rapid Syphilis Test (RSTs) as compared with rapid plasma reagin (RPR) when implemented in a Tanzanian setting, and to determine the relative impact of a quality ...assurance (QA) system on the cost of RST implementation. Methods The incremental costs for RPR and RST screening programmes in existing antenatal care settings in Geita District, Tanzania were collected for 9 months in subsequent years from nine health facilities that varied in size, remoteness and scope of antenatal services. The costs per woman tested and treated were estimated for each facility. A sensitivity analysis was constructed to determine the impact of parameter and model uncertainty. Findings In surveyed facilities, a total of 6362 women were tested with RSTs compared with 224 tested with RPR. The range of unit costs was $1.76-$3.13 per woman screened and $12.88-$32.67 per woman treated. Unit costs for the QA system came to $0.51 per woman tested, of which 50% were attributed to salaries and transport for project personnel. Conclusions Our results suggest that rapid syphilis diagnostics are very inexpensive in this setting and can overcome some critical barriers to ensuring universal access to syphilis testing and treatment. The additional costs for implementation of a quality system were found to be relatively small, and could be reduced through alterations to the programme design. Given the potential for a quality system to improve quality of diagnosis and care, we recommend that QA activities be incorporated into RST roll-out.
ApJ 957 46 (2023) We examine the wavelength dependence of radial light profiles based on
S\'ersic index $n$ measurements of 1067 galaxies with M$_*\geq$
10$^{9.5}$M$_\odot$ and in the redshift range ...$0.5 < z < 3$. The sample and
rest-frame optical light profiles are drawn from CANDELS$+$3D-HST; rest-frame
near-infrared light profiles are inferred from CEERS JWST/NIRCam imaging. $n$
shows only weak dependence on wavelength, regardless of redshift, galaxy mass
and type: on average, star-forming galaxies have $n = 1-1.5$ and quiescent
galaxies have $n = 3-4$ in the rest-frame optical and near-infrared. The strong
correlation at all wavelengths between $n$ and star-formation activity implies
a physical connection between the radial stellar mass profile and
star-formation activity. The main caveat is that the current sample is too
small to discern trends for the most massive galaxies (M$_* > 10^{11}M_\odot$).
PDF
